13G Filing: Highbridge Capital Management and Novelion Therapeutics Inc. (NVLN)

(a)

¨

Broker or dealer registered under Section 15 of the Act,

(b)

¨

Bank as defined in Section 3(a)(6) of the Act,

(c)

¨

Insurance Company as defined in Section 3(a)(19) of the Act,

(d)

¨

Investment Company registered under Section 8 of the Investment Company Act of 1940,

(e)

¨

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)

¨

Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),

(g)

¨

Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),

Item 2(a).	NAME OF PERSON FILING:
Item 2(b).	ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Item 2(c).	CITIZENSHIP:

Page 3 of 6 – SEC Filing

Item 1(a).	NAME OF ISSUER:

	The name of the issuer is Novelion Therapeutics Inc. (the “Company“).

Item 1(b).	ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

	The Company’s principal executive offices are located at 887 Great Northern Way, Suite 250, Vancouver, B.C., Canada V5T 4T5.

	This statement is filed by:

		Highbridge Capital Management, LLC 40 West 57th Street, 32nd Floor New York, New York 10019 Citizenship: State of Delaware
	The foregoing person is hereinafter sometimes referred to as the “Reporting Person.”

Item 2(d).	TITLE OF CLASS OF SECURITIES:

	Common Shares, without par value (the “Common Shares“).

Item 2(e).	CUSIP NUMBER:
	67001K202